Azitra
Branford, United States · Biotechnology, Therapeutics · 12 employees
Azitra is a clinical-stage biopharmaceutical company developing precision dermatology therapies using engineered strains of S. epidermidis. Its lead program, ATR-12, is in a Phase 1b trial for Netherton syndrome, a rare and life-threatening skin disease with no approved treatments. Azitra is also advancing ATR-04, currently in a Phase 1/2 trial, to treat EGFR inhibitor–associated skin toxicity, a
Funding history
- Series private placement — $10.5M — Mar 2026
- Funding Round — $5.0M — Nov 2025
- Funding Round — $4.4M — Oct 2022
- Funding Round — $1.0M — Jan 2021
- Series series b — Undisclosed — Oct 2020
Recent signals
- Mar 19, 2026: Raised $10.5M in Series private placement
- Dec 16, 2025: SEC 8-K (5.01): On December 16, 2025, Azitra, Inc. received a notice from NYSE American LLC confirming acceptance of its plan to regain compliance with listing standards related to stockholders' equity, necessitated by a previous deficiency letter received on October 1, 2025. This acceptance provides the Company until April 1, 2027, to meet the required minimum stockholders' equity under Section 1003(a)(ii) of the NYSE American Company Guide. The acceptance signifies a strategic opportunity for Azitra to implement corrective measures essential for maintaining its public listing, thereby potentially stabilizing investor confidence and business operations moving forward.
- Nov 25, 2025: Raised $5.0M
- Nov 24, 2025: SEC 8-K (1.01): On November 24, 2025, Azitra, Inc. entered into a securities purchase agreement with a single institutional investor. This agreement involves the issuance and sale of securities in a private placement offering, priced at a premium to market in compliance with NYSE regulations. The financial terms and the amount of securities involved were not specified, but the transaction is significant as it reflects a strategic move to secure funding through a specialized investor. This agreement is expected to impact the company's liquidity and operations positively.
- Apr 24, 2025: Azitra Announces Share Purchase Agreement with Alumni Capital for $20 Million Funding Partnership
- Jul 11, 2023: Azitra Co-Founder Travis Whitfill Returns as Operating Chief - MarketWatch
- Oct 12, 2022: Raised $4.4M
- Jan 19, 2021: Raised $1.0M
See plans & pricing → Track Azitra’s funding, hiring, and signals — with verified contacts — on Fundz.